UFP Technologies Inc. (UFPT) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. UFP Technologies, Inc. is a contract development and manufacturing organization specializing in single-use and single-patient medical devices. The company operates as a single reportable segment, with approximately 93% of net sales derived from the medical market. As of April 30, 2026, there were 7,736,939 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $154.2 million | $148.1 million |
| Gross Profit | $44.4 million | $42.2 million |
| Gross Margin | 28.8% | 28.5% |
| Operating Income | $23.4 million | $23.1 million |
| Net Income | $17.5 million | $17.2 million |
| Diluted EPS | $2.24 | $2.21 |
| Operating Cash Flow | $3.2 million | $13.8 million |
| Total Debt (Outstanding) | $137.6 million | N/A |
| Cash and Equivalents | $20.0 million | $14.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.1% year-over-year, driven by a 5.9% increase in medical market sales (specifically Robotic Surgery and Interventional/Surgical sub-markets). This was partially offset by a 15% decline in non-medical sales due to customer destocking.
- Profitability: Gross margin improved slightly to 28.8% due to increased efficiencies. Operating income rose marginally to $23.4 million despite higher SG&A expenses.
- Expenses: Selling, General, and Administrative (SG&A) expenses increased 12.3% to $21.0 million, attributed to increased headcount, non-recurring legal expenses ($0.5 million), and higher stock-based compensation ($0.6 million increase).
- Interest Expense: Net interest expense decreased significantly to $1.7 million from $2.8 million in the prior year due to lower average debt levels.
- Cash Flow: Operating cash flow declined to $3.2 million from $13.8 million, primarily due to a $15.7 million increase in receivables driven by higher sales volume in March 2026.
Outlook, Risks, and Unusual Items
- Tariff Refunds: Following a February 2026 Supreme Court ruling declaring certain IEEPA tariffs unconstitutional, the company expects to receive reimbursements via vendor credits in coming quarters. Tariff impact decreased in Q1 2026 compared to late 2025.
- Cyber Incident: A cybersecurity incident was detected on February 14, 2026. Management states it has not had a material impact on financial systems or operations, though investigation is ongoing.
- Workforce Issues: The company continues to address the "AJR Labor Issue" from 2025, involving workforce turnover and training inefficiencies at the AJR Enterprises facility.
- Geopolitical Risks: The filing highlights risks associated with the conflict between the U.S., Israel, and Iran, which could disrupt global supply chains and increase petroleum-based polymer costs.
- Customer Concentration: Two customers (Stryker and Intuitive Surgical SARL) accounted for approximately 46.9% of total net sales in Q1 2026.
Investor Verification Checklist
- Receivables Quality: Verify the collectability of the $15.7 million increase in receivables, noting that two customers represent nearly 42% of gross receivables.
- Tariff Reimbursement Timing: Monitor the actual receipt of vendor credits and CBP refunds related to the unconstitutional tariff ruling to assess future margin impacts.
- Cyber Incident Aftermath: Track any future disclosures regarding litigation, regulatory fines, or operational disruptions stemming from the February 2026 cyber incident.
- Destocking Duration: Confirm the timeline for the end of customer destocking in the Wound Care sub-market, currently expected to persist through Q3 2026.
- Debt Covenants: Review compliance with the fixed-charge coverage and debt-to-EBITDA covenants under the $275 million credit facility, particularly given the fluctuating operating cash flow.